ArticleCell death & disease2026
UBE3A-mediated mH2A1 Ubiquitination activates TERT transcription to promote senescence resistance in pancreatic cancer.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pancreatic cancer is a highly aggressive tumor with a poor prognosis. The ubiquitin-proteasome system is crucial in maintaining protein homeostasis and regulating cellular senescence, thereby influencing tumorigenesis and progression; however, the specific mechanisms underlying this process remain unclear. Ubiquitin protein ligase E3A (UBE3A) is associated with various tumors; however, its potential role in pancreatic cancer warrants further investigation. The effects of UBE3A on cellular senescence were evaluated through in vitro and in vivo experiments, including SA-β-gal staining, EdU assays, detection of senescence-associated markers, and the establishment of subcutaneous xenograft and liver metastasis models. Mechanistic studies utilized Ub-MS, IP-MS, ChIP-seq, and RNA-seq to explore downstream pathways, followed by validation through ubiquitination assays, ChIP-qPCR, and dual-luciferase reporter assays. Our results showed that UBE3A was significantly upregulated in pancreatic cancer tissues and correlated with poor patient outcomes. Functional studies have demonstrated that UBE3A inhibits cellular senescence in pancreatic cancer cells, thereby promoting tumor proliferation and metastasis. Mechanistically, the histone variant macroH2A1 (mH2A1) recruits EZH2 to mediate H3K27me3 modification, repressing Telomerase reverse transcriptase (TERT) transcription. UBE3A interacts with mH2A1 through its N-terminal domain, leading to K48-linked polyubiquitination at the K167 residue, which accelerates mH2A1 degradation and upregulates TERT, enhancing the anti-senescence capacity of pancreatic cancer cells. Inhibition of UBE3A combined with the senolytic agent ABT‑263 induced apoptosis and inhibited tumor growth. The UBE3A/mH2A1/TERT axis enhances the anti-senescence capacity of pancreatic cancer cells and drives malignant progression, suggesting that UBE3A may serve as a novel therapeutic target for pancreatic cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.